Chronic Obstructive Pulmonary Disease (COPD) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

 Chronic Obstructive Pulmonary Disease (COPD) is a significant cause of chronic morbidity and mortality throughout the world. Many people suffer from this disease for years and die prematurely from its complications. COPD is the fourth leading cause of death globally, and further increases in its prevalence and mortality can be predicted in the coming decades. Chronic inflammation causes structural changes and narrowing of the small airways. Destruction of the lung parenchyma, also by inflammatory processes, leads to the loss of alveolar attachments to the small airways and decreases lung elastic recoil; in turn, these changes diminish the ability of the airways to remain open during expiration. The airflow limitation is best measured by spirometry, as this is the most widely available, reproducible lung function test. The impact of COPD on an individual patient depends not just on the degree of airflow limitation but also the severity of symptoms. There is only an imperfect relationship between the degree of airflow limitation and the presence of symptoms. Spirometric staging, therefore, is a pragmatic approach aimed at practical implementation and should only be regarded as an educational tool and a general indication of the initial approach to management.

 

The prevalence of COPD in the USA varies from 6% to 11% in the adult population. The American Lung Association reports ~14 million American adults had been diagnosed with COPD. However, nearly 24 million American adults have impaired lung function, suggesting that COPD is underdiagnosed.

 

The competitive landscape includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Chronic Obstructive Pulmonary Disease (COPD) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Chronic Obstructive Pulmonary Disease (COPD) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Chronic Obstructive Pulmonary Disease (COPD) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          MEDI3506        AstraZeneca     Phase 3

2          TD-4208           Theravance Biopharma  Phase 2

3          SAR440340      Sanofi   Phase 3

4          Inhaled treprostinil solution         United Therapeutics      Phase 2

5          Tezepelumab    Kimera Society Inc        Phase 2

6          CDX-0159         Verona Pharma plc        Phase 3

7          Tiotropium bromide inhalation solution    Nephron Pharmaceuticals            Phase 2

8          Astegolimab      Genentech, Inc. Phase 2

9          CHF 4226         Chiesi Farmaceutici S.p.A.         Phase 2

10        Flutiform           Mundipharma Research Limited Phase 2/3

Continued